These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 9516230)
1. The CDKN2A tumor-suppressor locus--a tale of two proteins. Clurman BE; Groudine M N Engl J Med; 1998 Mar; 338(13):910-2. PubMed ID: 9516230 [No Abstract] [Full Text] [Related]
3. CDKN2A mutations in multiple primary melanomas. Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223 [TBL] [Abstract][Full Text] [Related]
4. Role of the CDKN2A locus in patients with multiple primary melanomas. Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862 [TBL] [Abstract][Full Text] [Related]
5. CDKN2A mutation and deletion status in thin and thick primary melanoma. Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737 [TBL] [Abstract][Full Text] [Related]
6. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521 [TBL] [Abstract][Full Text] [Related]
7. [From gene to disease; from p16 to melanoma]. Gruis NA; Bergman W Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670 [TBL] [Abstract][Full Text] [Related]
8. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. Petronzelli F; Sollima D; Coppola G; Martini-Neri ME; Neri G; Genuardi M Genes Chromosomes Cancer; 2001 Aug; 31(4):398-401. PubMed ID: 11433531 [TBL] [Abstract][Full Text] [Related]
9. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182 [TBL] [Abstract][Full Text] [Related]
10. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641 [TBL] [Abstract][Full Text] [Related]
11. CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702 [TBL] [Abstract][Full Text] [Related]
12. Melanoma genetics: an update on risk-associated genes. Udayakumar D; Tsao H Hematol Oncol Clin North Am; 2009 Jun; 23(3):415-29, vii. PubMed ID: 19464594 [TBL] [Abstract][Full Text] [Related]
13. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB; Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043 [TBL] [Abstract][Full Text] [Related]
14. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer. Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771 [TBL] [Abstract][Full Text] [Related]
15. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M; J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564 [TBL] [Abstract][Full Text] [Related]
16. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491 [TBL] [Abstract][Full Text] [Related]
17. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. Bloethner S; Hemminki K; Thirumaran RK; Chen B; Mueller-Berghaus J; Ugurel S; Schadendorf D; Kumar R Melanoma Res; 2006 Aug; 16(4):297-307. PubMed ID: 16845325 [TBL] [Abstract][Full Text] [Related]
18. Phenotypic variation in familial melanoma: consequences for predictive DNA testing. Bergman W; Gruis NA Arch Dermatol; 2007 Apr; 143(4):525-6. PubMed ID: 17438187 [No Abstract] [Full Text] [Related]